BACKGROUND: The aim of the study was to determine whether patients with obsessive-compulsive disorder (OCD) resistant to drug therapy may improve their condition using intensive, systematic cognitive behavioral therapy (CBT) lasting for 6 weeks, and whether it is possible to predict the therapeutic effect using demographic, clinical, and selected psychological characteristics at baseline. METHODS: Sixty-six OCD patients were included in the study, of which 57 completed the program. The diagnosis was confirmed using the structured Mini International Neuropsychiatric Interview. Patients were rated using the objective and subjective forms of the Yale-Brown Obsessive Compulsive Scale, objective and subjective forms of the Clinical Global Impression, Beck Anxiety Inventory, Beck Depression Inventory, Dissociative Experiences Scale, 20-item Somatoform Dissociation Questionnaire, and the Sheehan Disability Scale before their treatment, and with subjective Yale-Brown Obsessive Compulsive Scale, objective and subjective Clinical Global Impression, Beck Anxiety Inventory, and Beck Depression Inventory at the end of the treatment. Patients were treated with antidepressants and daily intensive group CBT for the 6-week period. RESULTS: During the 6-week intensive CBT program in combination with pharmacotherapy, there was a significant improvement in patients suffering from OCD resistant to drug treatment. There were statistically significantly decrease in the scores assessing the severity of OCD symptoms, anxiety, and depressive feelings. A lower treatment effect was achieved specifically in patients who 1) showed fewer OCD themes in symptomatology, 2) showed a higher level of somatoform dissociation, 3) had poor insight, and 4) had a higher initial level of overall severity of the disorder. Remission of the disorder was more likely in patients who had 1) good insight, 2) a lower initial level of anxiety, and 3) no comorbid depressive disorder.

Department of Psychiatry Faculty of Medicine and Dentistry Palacky University Olomouc University Hospital Olomouc Olomouc Czech Republic

Department of Psychology Faculty of Arts Charles University Prague Prague Czech Republic

Faculty of Humanities Charles University Prague Prague Czech Republic

Zobrazit více v PubMed

Hollander E, Kim S, Braun A, Simeon D, Zohar J. Cross-cutting issues and future directions for the OCD spectrum. Psychiatry Res. 2009;170(1):3–6. PubMed

American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, Fifth Ed DSM-5. Arlington: American Psychiatric Association; 2013.

Eisen JL, Goodman WK, Keller MB, et al. Patterns of remission and relapse in obsessive-compulsive disorder: a two–year prospective study. J Clin Psychiatry. 1999;60:346–351. PubMed

Steketee G, Henninger NJ, Pollard CA. Predicting treatment outcomes for obsessive-compulsive disorder: effects of comorbidity. In: Goodman WK, Rudorfer MV, Mase JD, editors. Obsessive-Compulsive Disorder: Contemporary Issues in Treatment. Mahwah, NJ: Lawrence Erlbaum Associates; 2000. pp. 257–274.

Nestadt G, Samuels J, Riddle MA, et al. The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD Family Study. Psychol Med. 2001;31(3):481–487. PubMed

Yaryura-Obias MA, Pinto A, Neziroglu F. The integration of primary anorexia nervosa and obsessive–compulsive disorder. Eat Weight Disord. 2001;6:174–180. PubMed

Maina G, Albert U, Salvi V, Pessina E, Bogetto F. Early-onset obsessive-compulsive disorder and personality disorders in adulthood. Psychiatry Res. 2008;158(2):217–225. PubMed

Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005;66(4):515–520. PubMed

Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive–compulsive disorder. Psychiatr Serv. 2003;54(8):1111–1118. PubMed

Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1997;65:44–52. PubMed

van Balkom AJ, de Haan E, van Oppen P, Spinhoven P, Hoogduin KA, van Dyck R. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis. 1998;186(8):492–499. PubMed

Foa EB. Failure in treating obsessive compulsives. Behav Res Ther. 1997;17:169–176. PubMed

Steketee G, Shapiro LJ. Predicting behavioral treatment outline for agoraphobia and obsessive-compulsive disorder. Clin Psychol Rev. 1995;15:317–346.

Steketee G, Chambless DL, Tranm G. Effects of Axis I and II comorbidity on behavior therapy outcome for obsessive compulsive disorder and agoraphobia. Compr Psychiatry. 2011;42:76–86. PubMed

Salkovskis PM, Harrison J. Abnormal and normal obsessions: a replication. Behav Res Ther. 1984;22:549–552. PubMed

Praško J, Pašková B, Záleský R, et al. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. Neuroendocrinol Lett. 2006;27:327–332. PubMed

Basoglu M, Lax T, Kasvikis Y, Marks IM. Predictors of improvement in obsessive-compulsive disorder. J Anxiety Disord. 1988;2:299–317.

Bartlett AE, Drummond LM. Hysterical conversion and dissociation arising as a complication of behavioral psychotherapy treatment of obsessive-compulsive neurosis. Br J Med Psychol. 1990;63(2):109–115. PubMed

Goff DC, Olin JA, Jenike MA, Baer L, Buttolph ML. Dissociative symptoms in patients with obsessive-compulsive disorder. J Nerv Ment Dis. 1992;180:332–337. PubMed

Rufer M, Held D, Cremer J, et al. Dissociation as a predictor of cognitive behavior therapy outcome in patients with obsessive-compulsive disorder. Psychother Psychosom. 2006;75:40–46. PubMed

Spitzer C, Barnow S, Freyberger HJ, Grabe HJ. Recent developments in the theory of dissociation. World Psychiatry. 2006;5:82–86. PubMed PMC

March JS, Frances A, Carpenter D, Kahn D. Expert consensus guidelines: treatment of obsessive compulsive disorder. J Clin Psychol. 1997;58:1–72.

Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive compulsive disorder. Int Clin Psychopharmacol. 1990;5:17–30. PubMed

Cottraux J, Note I, Yao SN, et al. A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder. Psychother Psychosom. 2001;70:288–297. PubMed

Foa EB, Sacks MB, Tolin DF, Prezworski A, Amir N. Inflated perception of responsibility for harm in OCD patients with and without checking compulsions: a replication and extension. J Anxiety Disord. 2002;16(4):443–453. PubMed

Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162(1):151–161. PubMed

Kampman M, Keijsers GP, Hoogduin CA, Verbraak MJ. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatr Scand. 2002;106(4):314–319. PubMed

Romanelli RJ, Wu FM, Gamba R, Mojtabai R, Segal JB. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials. Depress Anxiety. 2014;31(8):641–652. PubMed

Kozak MJ, Foa EB, McCarthy PR. Assessment of obsessive-compulsive disorder. The NIMH-sponsored collaborative study. In: Goodman WK, Rudorfer MV, Maser JD, editors. Obsessive-Compulsive Disorder: Contemporary Issues in Treatment. Mahwah, NJ: Lawrence Erlbaum Associates; 1988. pp. 501–530.

Keeley ML, Storch EA, Merlo LJ, Geffken GR. Clinical predictors of response to cognitive-behavioral therapy for obsessive-compulsive disorder. Clin Psychol Rev. 2008;28(1):118–130. PubMed

Karno M, Golding JM, Sorensen SB, Burnam MA. The prevalence of the obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45:1094–1099. PubMed

Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 1999;156(9):1409–1416. PubMed

Saxena S, Maidment KM, Vapnik T, et al. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment. J Clin Psychiatry. 2002;63:21–27. PubMed

Pigott TA, L’Heureux F, Dubbert B, Bernstein S, Murphy DL. Obsessive compulsive disorder: comorbid conditions. J Clin Psychiatry. 1994;55:15–27. PubMed

Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry. 1995;56(8):368–373. PubMed

Alonso P, Menchon JM, Pifarre J, et al. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry. 2001;62:535–540. PubMed

Hantouche EG, Bouhassira M, Lancrenon S. Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: Phase III National DRT-TOC Study. Encephale. 2000;26:73–83. PubMed

Shetti CN, Reddy YC, Kandavel T, et al. Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry. 2005;66:1517–1523. PubMed

Saxena S, Brody AL, Maidment KM, Baxter LR., Jr Paroxetine treatment of compulsive hoarding. J Psychiatr Res. 2007;41:481–487. PubMed PMC

Denys D, van Nieuwerburgh F, Deforce D, Westenberg HGM. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry. 2007;68:747–753. PubMed

Mezinárodní klasifikace nemocí. 10. revize . Duševní poruchy a poruchy chování: Diagnostická kritéria pro výzkum. (přeloženo z anglického originálu) Praha: Psychiatrické centrum; 1996. International Classification of the Diseases - 10th edition. Czech.

Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22–33. PubMed

Amorim P. Mini International Neuropsychiatric Interview (MINI): brief interview validation for diagnosing mental disorders. Rev Bras Psiquiatr. 2000;22(3):106–115.

Pinninti NR, Madison H, Musser E, Rissmiller D. MINI International Neuropsychiatric Schedule: clinical utility and patient acceptance. Eur Psychiatry. 2003;18:361–364. PubMed

Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989;46:1012–1016. PubMed

Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006–1011. PubMed

Raszka M, Praško J, Tintěra J, Horáček J. Depersonalizační a derealizační syndrom u pacientky s úzkostně depresivní poruchou v obraze 18FDG PET [Depersonalization and derealization syndrome in patients with anxiety-depressive disorder in the picture of 18FDG PET. Case report] Kazuistika Psychiatrie. 2009;13:33–38. Czech.

Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: U.S. DHEW; 1976.

Zaider TI, Heimberg RG, Fresco DM, Schneier FR, Liebowitz MR. Evaluation of the Clinical Global Impression Scale among individuals with social anxiety disorder. Psychol Med. 2003;33:611–622. PubMed

Beck AT, Emery G. Anxiety Disorders and Phobias: A Cognitive Perspective. New York: Basic Books; 1985.

Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893–897. PubMed

De Ayala RJ, Vonderharr-Carlson DJ, Kim D. Assessing the reliability of the Beck Anxiety Inventory score. Educ Psychol Meas. 2005;65:742–756.

Magán I, Sanz J, García-Vera MP. Psychometric properties of a Spanish version of the Beck Anxiety Inventory (BAI) in general population. Span J Psychol. 2008;11(2):626–640. PubMed

de Beurs E, Wilson KA, Chambless DL, Goldstein AJ, Feske U. Convergent and divergent validity of the Beck Anxiety Inventory for patients with panic disorder and agoraphobia. Depress Anxiety. 1997;6(4):140–146. PubMed

Beck AT, Steer RA, Ball R, Ranieri WF. Comparison of Beck depression inventories-IA and -II in psychiatric outpatients. J Pers Assess. 1996;67(3):588–597. PubMed

Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7:151–169. PubMed

Preiss M, Vaciř K. Beckova sebeposuzovací škála depresivity pro dospělé – BDI-II [Beck self-report depression scale for adults – BDI-II] Brno: Psychodiagnostika; 1999. Czech.

Bernstein EM, Putnam FW. Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis. 1986;174:727–735. PubMed

Ptacek R, Bob P, Paclt I. Škála disociativních zkuseností – česká verze [Dissociative Experiences Scale – Czech version] Cesk Psychol. 2006;50(3):262–272.

Nijenhuis ERS, Spinhoven P, Van Dyck R, Van der Hart O, Vanderlinden J. The development and psychometric characteristics of the Somatoform Dissociation Questionnaire (SDQ-20) J Nerv Ment Dis. 1996;184:688–694. PubMed

Farina B, Mazzotti E, Pasquini P, Nijenhuis E, Di Giannantonio M. Somatoform and psychoform dissociation among students. J Clin Psychol. 2011;67(7):665–672. PubMed

Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Clin Psychopharmacol. 1996;11(suppl 3):89–95. PubMed

Coles T, Coon C, DeMuro C, McLeod L, Gnanasakthy A. Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2014;19(10):887–895. PubMed PMC

Bonham CA, Uhlenhuth E. Disability and comorbidity: diagnoses and symptoms associated with disability in a clinical population with panic disorder. Psychiatry J. 2014;2014:619727. PubMed PMC

Vigne P, de Menezes GB, Harrison BJ, Fontenelle LF. A study of poor insight in social anxiety disorder. Psychiatry Res. 2014;219(3):556–561. PubMed

Camuri G, Oldani L, Dell’Osso B, et al. Prevalence and disability of comorbid social phobia and obsessive-compulsive disorder in patients with panic disorder and generalized anxiety disorder. Int J Psychiatry Clin Pract. 2014;18(4):248–254. PubMed

Piane GM, Smith TC. Building an evidence base for the co-occurrence of chronic disease and psychiatric distress and impairment. Prev Chronic Dis. 2014;23(11):E188. PubMed PMC

Praško J, Janů L, Junek P. Obsedantně kompulzivní porucha. In: Raboch J, Uhlikova P, Hellerova P, Anders M, Susta M, editors. Vodítka léčebné péče – úzkostné a neurotické poruchy [Obsessive compulsive disorders. Guidelines for treatment care - anxiety and neurotic disorders] Praha: Česká psychiatrická společnost; 2024. pp. 113–118. Czech.

Nakao T, Nakatani E, Nabeyama M, Yoshioka K, Tomita M, Nakagawa A. Duration effect on neuropsychological function and treatment response of OCD. Seishin Shinkeigaku Zasshi. 2005;107(12):1286–1298. PubMed

Kopřivová J, Congedo M, Horáček J, et al. EEG source analysis in obsessive-compulsive disorder. Neurophysiol Clin. 2011;122:1735–1743. PubMed

Raszka M, Prasko J, Koprivova J, Novak T, Adamcova K. Psychological dissociation in obsessive-compulsive disorder is associated with anxiety level but not with severity of obsessive-compulsive symptoms. Neuroendocrinol Lett. 2009;30(5):624–628. PubMed

Belloch A, Del Valle G, Morillo C, Carrió C, Cabedo E. To seek advice or not to seek advice about the problem: the help-seeking dilemma for obsessive-compulsive disorder. Soc Psychiatry Psychiatr Epidemiol. 2009;44(4):257–264. PubMed

Demet MM, Deveci A, Taşkin EO, et al. Risk factors for delaying treatment seeking in obsessive-compulsive disorder. Compr Psychiatry. 2010;51(5):480–485. PubMed

Subramaniam M, Abdin E, Vaingankar JA, Chong SA. Obsessive – compulsive disorder: prevalence, correlates, help-seeking and quality of life in a multiracial Asian population. Soc Psychiatry Psychiatr Epidemiol. 2012;47(12):2035–2043. PubMed

Wang X, Cui D, Wang Z, et al. Cross-sectional comparison of the clinical characteristics of adults with early-onset and late-onset obsessive compulsive disorder. J Affect Disord. 2012;136(3):498–504. PubMed

Vaingankar JA, Rekhi G, Subramaniam M, Abdin E, Chong SA. Age of onset of life-time mental disorders and treatment contact. Soc Psychiatry Psychiatr Epidemiol. 2013;48(5):835–843. PubMed

Pena-Garijo J, Edo Villamón S, Meliá de AlCba A, Ruipérez MÁ. Personality disorders in obsessive-compulsive disorder: a comparative study versus other anxiety disorders. Scientific World Journal. 2013;21:856846. PubMed PMC

Kampman M, Keijsers GP, Hoogduin CA, Hendriks GJ. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry. 2002;63(9):772–777. PubMed

Weissman MM, Bland RC, Canino GJ, et al. The cross national epidemiology of obsessive compulsive disorder. J Clin Psychiatry. 1994;55(3 suppl):5–10. PubMed

Hollander E, Greenwald S, Neville D, Johnson J, Hornig CD, Weissman MM. Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiologic sample. Depress Anxiety. 1996–1997;4(3):111–119. PubMed

Torres AR, Moran P, Bebbington P, et al. Obsessive-compulsive disorder and personality disorder: evidence from the British National Survey of Psychiatric Morbidity 2000. Soc Psychiatry Psychiatr Epidemiol. 2006;41(11):862–867. PubMed

Pastucha P, Prasko J, Grambal A, Latalova K, Sigmundova Z, Tichackova A. Dissociative disorder and dissociation – comparison with healthy controls. Neuro Endocrinol Lett. 2009;30(6):769–773. PubMed

Prasko J, Raszka M, Diveky T, et al. Obsessive compulsive disorder and dissociation – comparison with healthy controls. Biomed Pap. 2010;154(2):179–183. PubMed

Lochner C, Seedat S, Hemmings SM, Moolman-Smook JC, Kidd M, Stein DJ. Investigating the possible effects of trauma experiences and 5-HTT on the dissociative experiences of patients with OCD using path analysis and multiple regression. Neuropsychobiology. 2007;56(1):6–13. PubMed

Belli H, Ural C, Yesilyurt S, Vardart MK, Akbudak M, Oncu F. Childhood trauma and dissociation in patients with obsessive-compulsive disorder. West Indian Med J. 2013;62(1):39–44. PubMed

Semiz UB, Inanc L, Bezgin CH. Are trauma and dissociation related to treatment resistance in patients with obsessive-compulsive disorder? Soc Psychiatry Psychiatr Epidemiol. 2013;49(8):1287–1296. PubMed

Gava I, Barbui C, Aguglia E, et al. Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD) Cochrane Database Syst Rev. 2007;18(2):CD005333. PubMed

Lack CW. Obsessive-compulsive disorder: evidence-based treatments and future directions for research. World J Psychiatry. 2012;2(6):86–90. PubMed PMC

Knopp J, Knowles S, Bee P, Lovell K, Bower P. A systematic review of predictors and moderators of response to psychological therapies in OCD: do we have enough empirical evidence to target treatment? Clin Psychol Rev. 2013;33(8):1067–1081. PubMed

Pizarro M, Fontenelle LF, Paravidino DC, Yücel M, Miguel EC, de Menezes GB. An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder. Expert Opin Pharmacother. 2014;15(10):1391–1401. PubMed

Thompson-Hollands J, Edson A, Tompson MC, Comer JS. Family involvement in the psychological treatment of obsessive-compulsive disorder: a meta-analysis. J Family Psychol. 2014;2(3):287–298. PubMed PMC

Bystritsky A, Ackerman DL, Rosen RM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004;65(4):565–568. PubMed

Storch EA, Goddard AW, Grant JE, et al. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013;74(6):e527–e532. PubMed

O’Neill J. Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD. Evid Based Ment Health. 2014;17(2):58–59. PubMed

Dell’Osso B, Benatti B, Buoli M, et al. The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) Eur Neuropsychopharmacol. 2013;23(8):865–871. PubMed

Visser HA, van Oppen P, van Megen HJ, Eikelenboom M, van Balkom AJ. Obsessive-compulsive disorder; chronic versus non-chronic symptoms. J Affect Disord. 2014;15(2–154):169–174. PubMed

Olatunji BO, Rosenfield D, Tart CD, Cottraux J, Powers MB, Smits JA. Behavioral versus cognitive treatment of obsessive-compulsive disorder: an examination of outcome and mediators of change. J Consult Clin Psychol. 2013;81(3):415–428. PubMed

Mataix-Cols D, Boman M, Monzani B, et al. Population-based, multigenerational family clustering study of obsessive-compulsive disorder. JAMA Psychiatry. 2013;70(7):709–717. PubMed

Steketee G, Siev J, Fama JM, Keshaviah A, Chosak A, Wilhelm S. Predictors of treatment outcome in modular cognitive therapy for obsessive-compulsive disorder. Depress Anxiety. 2011;28(4):333–341. PubMed PMC

Eisen JL, Sibrava NJ, Boisseau CL, et al. Five-year course of obsessive-compulsive disorder: predictors of remission and relapse. J Clin Psychiatry. 2013;74(3):233–239. PubMed PMC

Shavitt RG, Valério C, Fossaluza V, et al. The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci. 2010;260(2):91–99. PubMed

Pigott TA, Seay S. Pharmacotherapy of obsessive-compulsive disorder. Int Rev Psychiatry (Abingdon, England) 1997;9:133–147.